News

The FGBI "ARRIAH" scientists have completed the development of the world's first method for differentiating the Sheba production strain from other strains of feline panleukopenia virus. The patent documents from the Russian Federation for this invention were received on December 3, 2025.

The importance of this development lies in the fact that a specific, validated virus strain – "Sheba" – is used in the production of vaccines against feline panleukopenia. The safety and efficacy of the vaccine directly depend on the accurate identification of this strain.

Clear and reliable genetic control methods are necessary to guarantee the origin of the vaccine's starting material and to prevent the inclusion of other strains.

The method developed by the FGBI "ARRIAH" is a highly sensitive, specific, yet simple and rapid technique that allows for the precise differentiation of the "Sheba" strain from any other variants of the panleukopenia virus. The technique is based on analyzing single nucleotide polymorphisms (SNPs)—small, unique differences in the genome structure that act as definitive genetic markers for the strain.

The center's scientists emphasized that the use of this method will provide an additional guarantee of quality in the production of vaccine preparations, help prevent possible identification errors, and enhance the reliability of protection for domestic carnivores.

For reference. Feline panleukopenia is a highly contagious and often fatal disease affecting cats and other members of the Felidae family. The virus replicates aggressively in the intestines, and mortality rates can reach 90%, depending on the clinical severity.

Protecting animal populations requires effective vaccination protocols and stringent disinfection, particularly in high-density environments like catteries (nurseries), shelters, and multi-cat households,

The production of vaccines against panleukopenia should be based on the use of relevant and genetically stable production strains.